Stryker Co. (NYSE:SYK) Stock Holdings Lifted by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. lifted its position in Stryker Co. (NYSE:SYK) by 5.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 51,886 shares of the medical technology company’s stock after acquiring an additional 2,883 shares during the period. Daiwa Securities Group Inc.’s holdings in Stryker were worth $18,682,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the business. NBT Bank N A NY boosted its holdings in shares of Stryker by 20.1% during the fourth quarter. NBT Bank N A NY now owns 4,240 shares of the medical technology company’s stock worth $1,527,000 after purchasing an additional 709 shares during the period. Sound View Wealth Advisors Group LLC lifted its position in Stryker by 63.0% in the 4th quarter. Sound View Wealth Advisors Group LLC now owns 8,026 shares of the medical technology company’s stock worth $2,890,000 after buying an additional 3,102 shares in the last quarter. Argentarii LLC acquired a new stake in shares of Stryker during the 4th quarter valued at $245,000. OFI Invest Asset Management acquired a new stake in shares of Stryker during the 4th quarter valued at $735,000. Finally, Coordinated Financial Services Inc. purchased a new position in shares of Stryker during the 4th quarter valued at $629,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Down 2.7 %

Shares of Stryker stock opened at $369.16 on Tuesday. The stock has a market capitalization of $140.87 billion, a P/E ratio of 47.57, a PEG ratio of 2.93 and a beta of 0.95. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The stock has a 50 day moving average price of $382.59 and a two-hundred day moving average price of $373.31. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the firm earned $3.46 earnings per share. Equities analysts expect that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.91%. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Analyst Ratings Changes

Several analysts recently issued reports on SYK shares. StockNews.com lowered Stryker from a “buy” rating to a “hold” rating in a report on Thursday, March 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $442.00 price objective on shares of Stryker in a research report on Wednesday, January 29th. Wells Fargo & Company boosted their target price on shares of Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 29th. Stifel Nicolaus raised their price target on shares of Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and an average target price of $421.90.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.